Fluconazole STELLA Liều dùng/Hướng dẫn sử dụng

The dose should be based on the nature and severity of the fungal infection. Treatment of infections requiring multiple dosing should be continued until clinical parameters or laboratory tests indicate that active fungal infection has subsided. An inadequate period of treatment may lead to recurrence of active infection.
Cryptococcosis: Treatment of cryptococcal meningitis: Loading dose: 400 mg on Day 1, subsequent dose: 200 mg to 400 mg once daily. Duration of treatment: Usually at least 6 to 8 weeks, in life threatening infections the daily dose can be increased to 800 mg.
Maintenance therapy to prevent relapse of cryptococcal meningitis in patients with high risk of recurrence: 200 mg once daily. Indefinitely at a daily dose of 200 mg.
Coccidioidomycosis: 1 capsule. Duration of treatment: 11 months up to 24 months or longer depending on the patient.
Treatment of mucosal candidiasis: Oropharyngeal candidiasis: Loading dose: 2 capsules on Day 1, subsequent dose: 1 capsule daily. Duration of treatment: 7 to 21 days (until oropharyngeal candidiasis is in remission).
Oesophageal candidiasis: Loading dose: 2 capsules on Day 1, subsequent dose: 1 capsule daily. Duration of treatment: 14 to 30 days (until oesophageal candidiasis is in remission).
Candiduria: 2 capsules daily. Duration of treatment: 7 to 21 days.
Longer periods may be used in patients with severely compromised immune function.
The prophylaxis of relapse of mucosal candidiasis in patients infected with HIV who are at high risk of experiencing relapse: Oropharyngeal candidiasis: 1 capsule daily.
Oesophageal candidiasis: 1 capsule daily.
Duration of treatment: An indefinite period for patients with chronic immune suppression.
Genital candidiasis: Adults: Acute vaginal candidiasis: A single oral dose 1 capsule.
Treatment and prophylaxis of recurrent vaginal candidiasis (4 or more episodes a year): 1 capsule every third day for a total of 3 doses (day 1, 4 and 7) followed by 1 capsule once weekly maintenance dose (6 months).
Candidal balanitis: A single oral dose 1 capsule.
Adolescents (from 12 to 17 years old): Safety and efficacy for genital candidiasis indication in paediatric population has not been established. If treatment for genital candidiasis is imperative, the posology should be the same as adults posology.
Dermatomycosis: Tinea pedis, tinea corporis, tinea cruris, dermal candida infections: 1 capsule once weekly.
Duration of treatment: 2 to 4 weeks, tinea pedis may require treatment for up to 6 weeks.
Tinea versicolor: 2 capsules once weekly, 1 to 3 weeks.
Tinea unguium (onychomycosis): 1 capsule once weekly. Treatment should be continued until infected nail is replaced (uninfected nail grows in). Regrowth of fingernails and toenails normally requires 3 to 6 months and 6 to 12 months, respectively. However, growth rates may vary widely in individuals, and by age. After successful treatment of long-term chronic infections, nails occasionally remain disfigured.
Prophylaxis of candidal infections in patients with prolonged neutropenia: 2 capsules. Treatment should start several days before the anticipated onset of neutropenia and continue for 7 days after recovery from neutropenia after the neutrophil count rises above 1000 cells per mm³.
Elderly: Dosage should be adjusted based on the renal function.
Renal impairment: No adjustments in single dose therapy are necessary. In patients (including paediatric population) with impaired renal function who will receive multiple doses of fluconazole, an initial dose of 1-2 capsules should be given, based on the recommended daily dose for the indication. After this initial loading dose, the daily dose (according to indication) should be based on the following table: see table.


Click on icon to see table/diagram/image


Patients on regular dialysis should receive 100% of the recommended dose after each dialysis; on non-dialysis days, patients should receive a reduced dose according to their creatinine clearance.
Hepatic impairment: Limited data are available in patients with hepatic impairment; therefore fluconazole should be administered with caution to patients with liver dysfunction.
Method of Administration: Fluconazol STELLA 150 mg is administered orally